These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 34414545)

  • 21. A Quantitative Assessment of Factors Affecting the Technological Development and Adoption of Companion Diagnostics.
    Luo D; Smith JA; Meadows NA; Schuh A; Manescu KE; Bure K; Davies B; Horne R; Kope M; DiGiusto DL; Brindley DA
    Front Genet; 2015; 6():357. PubMed ID: 26858745
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biomarkers and biomarker validation: a pathologist's guide to getting it right.
    Paver EC; Morey AL
    Pathology; 2024 Mar; 56(2):147-157. PubMed ID: 38195376
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Health Technology Assessment of companion diagnostics: experience of NICE.
    Byron SK; Crabb N; George E; Marlow M; Newland A
    Clin Cancer Res; 2014 Mar; 20(6):1469-76. PubMed ID: 24634470
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Challenges in the clinical implementation of precision medicine companion diagnostics.
    Keeling P; Clark J; Finucane S
    Expert Rev Mol Diagn; 2020 Jun; 20(6):593-599. PubMed ID: 32336167
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Health technology assessment and personalized medicine: are economic evaluation guidelines sufficient to support decision making?
    Husereau D; Marshall DA; Levy AR; Peacock S; Hoch JS
    Int J Technol Assess Health Care; 2014 Apr; 30(2):179-87. PubMed ID: 24806420
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Budget impact and cost-effectiveness: can we afford precision medicine in oncology?
    Doble B
    Scand J Clin Lab Invest Suppl; 2016; 245():S6-S11. PubMed ID: 27426412
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Economic Considerations in the Use of Novel Targeted Therapies for Lung Cancer: Review of Current Literature.
    Albaba H; Lim C; Leighl NB
    Pharmacoeconomics; 2017 Dec; 35(12):1195-1209. PubMed ID: 28861770
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Establishing the Evidence Bar for Molecular Diagnostics in Personalised Cancer Care.
    Schneider D; Bianchini G; Horgan D; Michiels S; Witjes W; Hills R; Plun-Favreau J; Brand A; Lawler M;
    Public Health Genomics; 2015; 18(6):349-58. PubMed ID: 26571110
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Addressing Challenges of Economic Evaluation in Precision Medicine Using Dynamic Simulation Modeling.
    Marshall DA; Grazziotin LR; Regier DA; Wordsworth S; Buchanan J; Phillips K; Ijzerman M
    Value Health; 2020 May; 23(5):566-573. PubMed ID: 32389221
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Value of Companion Diagnostics: Overcoming Access Barriers to Transform Personalised Health Care into an Affordable Reality in Europe.
    Wurcel V; Perche O; Lesteven D; Williams DA; Schäfer B; Hopley C; Jungwirth R; Postulka A; Pasmans R; Hermansson LL; Ott M; Glorioso V
    Public Health Genomics; 2016; 19(3):137-43. PubMed ID: 27237134
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A generalized health economic and outcomes research model for the evaluation of companion diagnostics and targeted therapies.
    Lee J; Tollefson E; Daly M; Kielb E
    Expert Rev Pharmacoecon Outcomes Res; 2013 Jun; 13(3):361-70. PubMed ID: 23763533
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness of precision medicine: a scoping review.
    Kasztura M; Richard A; Bempong NE; Loncar D; Flahault A
    Int J Public Health; 2019 Dec; 64(9):1261-1271. PubMed ID: 31650223
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lessons learned from the application of the HEcoPerMed guidance to three modeling case studies.
    Nagy B; Zelei T; Vellekoop H; Huygens S; Versteegh M; Mölken MR; Koleva-Kolarova R; Tsiachristas A; Wordsworth S; Szilberhorn L
    Per Med; 2023 Jul; 20(4):401-411. PubMed ID: 37694556
    [No Abstract]   [Full Text] [Related]  

  • 35. Rapid antigen detection and molecular tests for group A streptococcal infections for acute sore throat: systematic reviews and economic evaluation.
    Fraser H; Gallacher D; Achana F; Court R; Taylor-Phillips S; Nduka C; Stinton C; Willans R; Gill P; Mistry H
    Health Technol Assess; 2020 Jun; 24(31):1-232. PubMed ID: 32605705
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Decision Models for Assessing the Cost Effectiveness of Treatments for Pediatric Drug-Resistant Epilepsy: A Systematic Review of Economic Evaluations.
    Elliott J; van Katwyk S; McCoy B; Clifford T; Potter BK; Skidmore B; Wells GA; Coyle D
    Pharmacoeconomics; 2019 Oct; 37(10):1261-1276. PubMed ID: 31201643
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Systematic Review of Health Economic Evaluations of Diagnostic Biomarkers.
    Oosterhoff M; van der Maas ME; Steuten LM
    Appl Health Econ Health Policy; 2016 Feb; 14(1):51-65. PubMed ID: 26334528
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development of Companion Diagnostics.
    Mankoff DA; Edmonds CE; Farwell MD; Pryma DA
    Semin Nucl Med; 2016 Jan; 46(1):47-56. PubMed ID: 26687857
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Shedding Light on Reimbursement Policies of Companion Diagnostics in European Countries.
    Govaerts L; Simoens S; Van Dyck W; Huys I
    Value Health; 2020 May; 23(5):606-615. PubMed ID: 32389226
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A practical guide to value of information analysis.
    Wilson EC
    Pharmacoeconomics; 2015 Feb; 33(2):105-21. PubMed ID: 25336432
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.